Introduction
Epstein-Barr virus (EBV) is a ubiquitous human herpesvirus (1) . Primary infection occurs during infancy in the majority of people and is usually asymptomatic. Following primary infection the virus persists for life in the presence of humoral and cellular immune responses specific for virus components and virus-infected cells. EBV is thought to exist in vivo as a latent infection within the B lymphocyte compartment and to undergo periodic episodes of lytic replication with shedding of infectious virus in saliva (1, 2) . A delay in primary infection until after puberty results in 50% of individuals developing infectious mononucleosis (IM) (3) . EBV is also associated with a number of tumours including endemic Burkitt's lymphoma (BL) (4), undifferentiated nasopharyngeal carcinoma (5), certain types of Hodgkin's disease (6) and lymphomas in immunocompromised patients (7) .
EBV infection transforms and immortalizes B lymphocytes
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Transmitting editor: P. C. Doherty Received 14 January 1998, accepted 21 April 1998 in vitro allowing them to be cultured continuously as lymphoblastoid cell lines (LCL). These lines express virus-coded latency genes, which are Epstein-Barr nuclear antigens (EBNA) and latent membrane proteins (LMP) (1), several of which have transforming or transcriptional activating properties that make them potentially oncogenic (8) (9) (10) (11) . Treatment of EBV-infected B cells with phorbol 12-myristate 13-acetate (PMA), anti-Ig or T cell growth factor reactivates latent virus initiating a lytic infection in which new infectious virus is generated (12, 13) . Suppression of the immune system by drugs or infection with HIV is associated with an increased incidence of B cell lymphomas which express the same pattern of EBV latent antigens as LCL (14) . These observations suggest that mechanisms are active in vivo which prevent the expansion of latently infected B cells. In healthy individuals, control of EBV-infected B cell growth is thought to be mediated by MHC class I-restricted CD8 ϩ cytotoxic T cells. CD8 ϩ T cells recognizing peptide epitopes of the EBV latent proteins EBNA2, EBNA3a-c, LMP1 and LMP2a have been identified (15, 16) . Although high levels of antibodies to viral glycoproteins (17) and T h cells recognizing gp340, the major envelope glycoprotein, have been described (18) (19) (20) , the role of CD4 ϩ T cells in response to EBV infection and the cellular immune response to lytic cycle antigens have received less attention. Help from MHC class II-restricted CD4 ϩ T cells would be required for both antibody production and efficient generation of cytotoxic CD8 ϩ T cells. It is also possible that CD4 ϩ T cells exert other direct effects on EBV-infected B cells. A role for direct effects of CD4 ϩ T cells in controlling EBV is suggested by work on the tamarin model of EBV infection and lymphoma. In tamarins immunized with gp340, protection against EBV-induced lymphoma does not correlate with the presence of neutralizing antibody (21) , which implies that cell-mediated mechanisms of immune protection are important. However, tamarin MHC class I only has analogues of HLA-G and -F, and the main T cell responses identified following infection with EBV are MHC class II-restricted (22) .
Here we investigate the hypothesis that EBV-reactive CD4 ϩ T cells directly contribute to the control of EBV-infected B cell growth in humans.
Methods

Assessment of donor immune status and preparation of autologous LCL
Blood samples were collected from healthy adult volunteers by vacutainer (Becton Dickinson, Maylan, France) containing sodium citrate as an anti-coagulant. Peripheral blood lymphocytes (PBL) were prepared by centrifugation through lymphocyte preparation medium (Lymphoprep; ICN Flow, High Wycombe, UK). A sample of plasma was tested for the presence of antibodies to viral capsid antigen by immunofluoresence (17) . PBL were infected with the B958 strain of EBV and serial dilutions plated out in a regression assay to confirm the presence of an anti-viral cell-mediated response as described by others (23) . Microtitre wells containing cells at a dilution below that required for regression and which contained active B cell growth after 4 weeks were expanded to form LCL.
Generation of T cell lines
PBL were cultured in RPMI 1640/10% FCS or pooled human AB serum (Sigma) in a 2 ml volume at a density of 10 6 /ml. Expression of EBV lytic cycle antigens in LCL was induced by incubation in media containing 10 ng/ml PMA (Sigma) for 72 h. Proliferation of PMA-induced or resting LCL was blocked by incubation with 80 ng/ml mitomycin C (Sigma, Poole, UK) for 1 h. The LCL were washed 3 times in PBS prior to addition of PBL. PBL were stimulated on day 1 with mitomycin-treated autologous LCL at a ratio of 40 PBL:1 LCL. On day 10 the cells were washed and re-stimulated with mitomycin-treated autologous LCL at a ratio of 10 PBL:1 LCL. On day 14 and at weekly intervals thereafter T cell lines were re-stimulated with mitomycin-treated autologous LCL and 10 IU/ml IL-2 (22) . CD4 ϩ T cells were purified by magnetic cell sorting through a Minimacs column (Miltenyi Biotech). Cells were positively selected by staining with anti-CD4 ϩ mAb followed by goat anti-mouse paramagnetic conjugate (Miltenyi). CD8 ϩ lines were also established by magnetic cell sorting using anti-CD8 mAb. B cell blasts were cultured by stimulating PBL with monoclonal anti-CD40 and IL-4 on a feeder layer of Cdw 32 cells as described elsewhere (24) Flow cytometry CD4 ϩ /CD8 ϩ ratios were determined by flow cytometry using direct staining with anti-CD4-phycoerythrin (PE) (MT310) and anti-CD8-FITC (T8 ) antibodies (Dako, High Wycombe, UK Expression of CD95L on T cells was measured by flow cytometry as described elsewhere (25) . T cells were stimulated by the addition of PMA-activated LCL in the presence of the metalloprotease inhibitor BB-3103 (gift of Dr A. H. Drummond. British Biotech Pharmaceuticals, Oxford) as described (25) . The cells were stained with hamster antihuman CD95L Clone 4H9 (Gift of S. Nagata, Osaka Bioscience Institute) followed by biotinylated goat anti-hamster Ig (Vector, Burlingame, CA) and streptavidin-PE (Serotec, Oxford, UK) or with mouse anti-CD95L clone NOK1 (PharMingen) and goat anti-mouse FITC (Sigma).
Cytotoxic assay
A pellet of 10 6 target cells was resuspended in 25 ml HBSS containing 2 MBq of 51 Cr (Amersham, Amersham, UK), incubated at 37°C for 1 h and washed 4 times by centrifugation with PBS. Then 10 4 labelled cells in 100 µl of medium were placed in 96-well V-bottomed plates. After 5 h incubation 100 µl of supernatant was harvested and counted in a γ-counter (Compugamma; LKB, Bromma, Sweden).
Spontaneous 51 Cr release was determined from wells containing targets alone and total labelling determined from targets lysed with 0.5% Triton X-100. The percentage specific release was calculated as specific counts -spontaneous counts/total counts -spontaneous countsϫ100.
Growth inhibition assay
Replicate doubling dilutions of LCL, BL or other cell lines were prepared in round-bottomed 96-well plates starting at 2.4ϫ10 4 cells/well in row A. Then 2.4ϫ10 4 T cells were added to each well in columns 1-4 so that the effector target ratio was 1:1 in row A rising to 128:1 in row H. Columns 5-8 contained LCL or other cell lines with no T cells as controls. The remaining four columns contained T cells as before with the addition of 2.4ϫ10 3 mitomycin-treated, PMA-activated autologous LCL in each well to act as antigen stimulators. Plates were fed weekly with the replacement of 100 µl media.
Outgrowth of cell lines was assessed after 4 weeks by examining the wells for the presence of live cells using an inverted phase contrast microscope.
Induction of apoptosis by anti-CD95 antibody A 96-well tissue culture plate was coated by overnight incubation at 4°C with 100 µl of a 10 mg/ml solution of affinitypurified goat anti-mouse antibody in PBS (Sigma). The wells were washed with three changes of tissue culture medium and 100 µl of cells at 10 6 /ml were added to replicate wells. Then 100 µl of dilutions of monoclonal anti-CD95 (BG27; Serotec) dialysed against tissue culture media were added to half of the replicate wells while control wells received media alone. After 18 h incubation the cells were harvested and the proportion of apoptotic cells assayed by flow cytometry following propidium iodide staining of cellular DNA (26) . Then 10 6 cells were resuspended in 1 ml HBSS containing 0.5 mM EDTA and fixed by the dropwise addition of 2 ml 100% ethanol with continuous vortexing. The fixed cells were washed twice in PBS, and stained for 1 h at 37°C in PBS containing 5 g/ml propidium iodide and 4 µg/ml RNase type A (Sigma). Alternatively the growth of LCL was measured by [ 3 H]thymidine incorporation between 48 and 60 h of culture.
Induction of apoptosis by T cells
Induction of apoptosis by T cells was assayed by mixing equal numbers of LCL and T cells in 1 ml tissue culture wells. Aliquots of the mixed cells were removed at intervals. T cells were stained with a mixture of anti-CD3 and -CD2 mAb, followed by FITC-anti-mouse conjugate prior to fixation and staining with propidium iodide. The cells were analysed by two-color flow cytometry. Where indicated, 10 µg/ml purified hamster anti-CD95L (4H9) or 10 µg/ml of metalloprotease inhibitor BB-3103 was added during the incubation.
Detection of BZLF1
Cells were harvested, washed in PBS and counted. Then 10 6 cells were spun down in an Eppendorf tube and the supernatant carefully removed. The cell pellet was resuspended in 50 ml SDS loading buffer heated at 100°C for 5 min. Samples of 5 ml were run on 12% SDS-PAGE gels under reducing conditions and blotted onto PVDF membrane (Millipore). The membranes were blocked with PBS containing 1% BSA/0.1% Tween 20 (Sigma). Membranes were then incubated overnight with mAb to BZLF1 (BZ1 gift of Professor L. Young University of Birmingham) diluted 1:10 in blocking buffer and washed in five changes of PBS/Tween followed by goat anti-mouse alkaline phosphatase conjugate at a dilution of 1:10,000 for 1 h, and developed using Fast Blue and α-napthyl phosphate (Sigma).
Results
Phenotype of T cells responding to autologous LCL or PMAtreated autologous LCL
The majority of LCL in vitro express only EBV latent viral antigens, although all cultures do contain a proportion of cells which express EBV lytic cycle antigens. Stimulation with PMA can induce a higher proportion of cells to enter the viral lytic cycle. In the course of preliminary experiments aimed at assessing the cytotoxic T cell response to EBV lytic cycle antigens we noted a shift in the phenotype of T cells responding to autologous LCL in vitro which had been treated with PMA. PBL from six individuals responding to stimulation with autologous LCL had an average ratio of 45 Ϯ 5.8% CD8 ϩ T cells to 39 Ϯ 2.2 % CD4 ϩ T cells. If PMA-activated LCL were used the proportion of CD8 ϩ cells dropped to 25 Ϯ 5.8% with a corresponding rise to 61 Ϯ 5.3% for CD4 ϩ cells. Repeated re-stimulation of the T cells with PMA-activated LCL led to a progressive increase in the proportion of CD4 ϩ cells until CD8 ϩ cells were no longer detected in five out of six cases.
Responses in which CD4 ϩ T cells are predominant over CD8 ϩ T cells do not require PMA induction of LCL in all cases. One of the six individuals above had a response of 82% CD4 ϩ T cells after stimulation with autologous LCL that had not been treated with PMA. In the course of our studies we have detected two further individuals from 10 tested who have a response to autologous LCL dominated by CD4 ϩ T cells. The same individuals also have 10 times higher than average levels of neutralizing antibodies to gp340 (data not shown) indicating that they are responding strongly to lytic EBV antigens in vivo.
Influence of serum source and acyclovir on the expression of EBV lytic cycle antigens and CD4 ϩ T cell responses
We compared the responses of PBL to untreated LCL with LCL cultured in acyclovir which inhibits viral DNA polymerase, thereby limiting the completion of the virus lytic cycle and release of virus. Both the LCL and the PBL were cultured in human serum throughout this experiment. Wells containing 2ϫ10 6 PBL on day 1 were stimulated as described above with mitomycin-treated LCL on days 1, 10 and 14. The total number of cells and their phenotype were measured on day 21. PBL from three individuals yielded an average of 2.2 Ϯ 1.37ϫ10 6 cells compared to 1.7 Ϯ 0.57ϫ10 6 acyclovirtreated LCL. The CD4/CD8 ratio of cultures stimulated with untreated LCL was 48/39 compared with 46/39 for cultures stimulated with acyclovir-treated LCL. Also, treatment with acyclovir did not completely prevent the expression of lytic cycle antigens as shown by the continued detection of BZLF1. PMA activation of LCL in human serum restored the level of BZLF1 and the magnitude of the CD4 ϩ T cell response (data not shown).
It has been reported that some CD4 ϩ T cell clones raised against LCL cultured in FCS are less cytotoxic towards the same LCL cultured in human serum and may therefore be responding to exogenous antigens present in FCS (27) . The CD4 ϩ T cells described above cannot be responding to exogenous FCS antigens as these cells were grown in human serum. We therefore addressed the question of whether the reduction of the CD4 ϩ T cell responses attributed to FCS antigens could be due to alterations in the level of lytic cycle antigens expressed by LCL cultured in different serum.
Cultures were set up as described above. The responses of PBL to autologous LCL cultured in human serum were lower when compared to responses of PBL to LCL grown in FCS in terms of the total number of T cells present in cultures on day 21, although the ratio of CD4 ϩ to CD8 ϩ T cells was not greatly affected. However, this does not necessarily indicate that some T cells are responding to FCS. Cells cultured in human serum expressed lower levels of BZLF1 (data not shown) which is the first viral product at the beginning of the viral lytic cycle. Thus the data may equally indicate that many T cells are responding to this or other viral lytic cycle antigens.
Functional characterization of purified CD4 ϩ T cells CD4 ϩ T cell lines purified by MACS proliferated more in response to re-stimulation with PMA-activated LCL compared to untreated LCL (Fig. 1) . After 7 days live CD4 ϩ T cells were recovered from cultures stimulated either with PMA-activated or resting LCL. Although the numbers of cells from cultures stimulated with resting LCL was lower, they could be restimulated and grown a second time. In a separate experiment, we stimulated CD4 ϩ T cell lines raised against LCL with autologous B cell blasts generated using anti-CD40 and IL-4. There was an initial small growth response to B cell blasts; however, this was transient and all the T cells were dead on day 7 after re-stimulation, indicating that the survival of the CD4 ϩ T cells in question is dependent on the presence of viral antigens.
The ability of CD4 ϩ and CD8 ϩ T cell lines to mediate cytotoxic killing of LCL was tested (Fig. 1b) . CD8 ϩ T cells, which were also CD3 ϩ and therefore not NK cells, killed unstimulated LCL, PMA-activated LCL and the NK cell target K562. However, CD8 ϩ T cells consistently killed unstimulated LCL more effectively than PMA-activated LCL. In contrast, the CD4 ϩ T cell lines were poorly cytotoxic for all of the target cells tested. Despite their low levels of cytotoxic activity CD4 ϩ T cells were able to inhibit long-term growth of autologous LCL when mixed in culture (Fig. 2a) . These observations suggest that EBV-reactive CD4 ϩ T cells regulate LCL growth by a mechanism independent of classical cytotoxic killing.
The possibility that such control involved an interaction between CD95L expressed by the T cell and CD95 expressed on the target cell was tested. Growth of the CD95-susceptible line, Jurkat, was only slightly inhibited in co-cultures with CD4 ϩ T cells alone; however, the addition of CD4 ϩ T cells together with PMA-activated LCL resulted in complete inhibition of growth of Jurkat cells (Fig. 2b) . The addition of PMAactivated LCL alone had no effect on the growth of Jurkat cells (data not shown).
Expression of CD95 on LCL and susceptibility to killing by anti-CD95 antibody
Flow cytometric analysis demonstrated that LCL express CD95 as do Jurkat cells (Fig. 3a) . Two BL lines, Daudi and EB4, expressed minimal levels of CD95, whereas a third BL line Raji was strongly CD95 ϩ (Fig. 3a) . The NK target cell line, K562, was CD95 -. The susceptibility of these lines to CD95-induced apoptosis was measured directly using mAb to cross-link CD95 on the cell surface. After 18 h of incubation there was an increase in the proportion of apoptotic cells in cultures of Jurkat and LCL as determined by the proportion of cells with a sub-G 0 DNA content (Fig. 3b) . However, no increase in apoptosis was seen in any of the BL lines nor in K562 cells.
Not all LCL were equally inhibited by anti-CD95 antibody. The growth of three different LCL in the presence of increasing dilutions of anti-CD95 antibody showed that two of the lines were highly susceptible to killing by anti-CD95 antibody even at dilutions 100-fold less than optimal for flow cytometry staining (Fig. 3c) . The third line was much more resistant to CD95-mediated killing. The growth of the third line was also less effectively inhibited by autologous T cells when compared to the other two. All three lines expressed similar levels of CD95 and Bcl-2 (data not shown), and the reason for the observed differences in susceptibility is not known.
CD4 ϩ T cells mediate apoptosis of LCL through CD95-CD95L interaction
Co-culture experiments showed that growth inhibition of LCL and BL cell lines by LCL-activated CD4 ϩ T cells was identical to the pattern of CD95 susceptibility shown in Fig. 3b , i.e.
Jurkat and LCL growth was inhibited (Fig. 2) while CD4 ϩ T cells had no effect on Raji, EB4 or K562. There was a reduction in the rate of outgrowth of Daudi in the first week but thereafter the cells grew out and no wells showed any long-term inhibition (data not shown). The expression of CD95L on LCL-activated CD4 ϩ T cells was assessed by flow cytometry. CD95L was not detected on the surface of resting CD4 ϩ T cells (Fig. 4a) . Expression was enhanced following incubation for 18 h with PMAactivated LCL (Fig. 4b) . The level of CD95L expression stimulated by LCL was low but similar to that induced following treatment with PMA and ionomycin, which are activators of CD95L expression (25) .
In further experiments, we measured the effect of anti-CD95L antibody on the induction of LCL apoptosis by CD4 ϩ T cells in a co-culture system (Fig. 5) . Dual-color flow cytometry revealed that after 10 h co-incubation with CD4 ϩ T cells, the proportion of apoptotic LCL rose from 11 to 22%. Addition of a metalloprotease inhibitor to enhance expression of membrane-bound CD95L on T cells increased the proportion of apoptotic LCL to 31%. The proportion of apoptotic LCL was returned to background levels by the addition of antibody to CD95L (Fig. 5d) . Additional evidence that the induction of cell death by CD4 ϩ T cells is mediated by CD95L is found in the relative cell numbers recovered from each of the above cultures for the analysis. At time 0, the proportion of LCL was 33%. This dropped to 21% after 10 h incubation with CD4 ϩ T cells, and to 19% by the addition of CD4 ϩ T cells and metalloprotease inhibitor. The presence of anti-CD95L antibody increased the proportion of LCL to 44% of the cultured cells confirming their enhanced survival and growth. The above experiment was repeated 5 times giving similar results on three occasions. However, it is clear that a number of other parameters determine the outcome in this type of experiment such as the type and quality of the blocking antibody used. Also a high rate of Fas ligand turnover on the surface of some T cells may prevent the antibody to Fas ligand from masking all of the Fas ligand expressed. Some Fas ligand may be inaccessible to blocking antibody where it is at junctions between interacting B cells and T cells. The blocking of Fas-induced apoptosis in LCL by antibody to Fas ligand is clearly sensitive to certain conditions. Further investigation will be needed to resolve these issues.
Discussion
The results of this study demonstrate that both CD4 ϩ and CD8 ϩ T cells can be activated and proliferate in response to EBV-infected B cells. The higher level of CD4 ϩ T cells responding to PMA-activated LCL also suggests that the activation of CD4 ϩ T cells occurs primarily as a result of the presentation of lytic cycle antigens. This is unlikely to be a direct effect of PMA on the T cells as the LCL are extensively washed before addition to the culture. Furthermore, we have found several individuals who produce a CD4-dominated response to autologous LCL that have not been treated with PMA. Overall three out of 10 seropositive people we have tested have this CD4-dominated response. These same individuals also have higher than average levels of antibody to gp340 indicating that their immune system is responding to lytic cycle antigens in vivo and provides more circumstantial evidence that CD4 ϩ T cells are responding to lytic antigens. CD4 ϩ T cells specific for gp340 have been cloned and the clones proliferated in response to LCL but also responded to LCL treated with acyclovir (20) . Our observations that acyclovir treatment has little effect on the CD4 ϩ T cell response to LCL and does not completely prevent the expression of EBV lytic cycle antigens are consistent with these earlier results. Consequently, while it is clear that increases in viral lytic cycle antigen expression by LCL after treatment with PMA are associated with increased CD4 ϩ T cell responses, it has not been possible to eliminate either the CD4 ϩ T cell response or viral lytic cycle antigen expression using acyclovir.
In agreement with previous reports that T cell clones from seronegative individuals raised against LCL were all CD4 ϩ (27) we have also demonstrated a strong CD4 ϩ T cell response in seronegative adults to LCL. It was reported that some CD4 ϩ T cell clones raised in FCS had reduced cytotoxic activity against autologous LCL cultured in human serum and were thought to be specific for FCS antigens (27) . This may not be the case, however, as LCL cultured in human serum express lower levels of BZLF1, the main EBV lytic cycle activator, compared to LCL grown in FCS. This reduced expression of lytic cycle antigens could equally account for the reduced cytotoxicity of primary CD4 ϩ T cell clones toward LCL cultured in human serum reported previously (27) and the reduced proliferative response of CD4 ϩ T cells to LCL grown in human serum reported here.
Recently an EBV-associated superantigen which stimulates V β 13 CD4 ϩ T cells has been described that is expressed on PMA-activated LCL (28) . However only some of the CD4 ϩ T cells in this study from either seronegative or seropositive adults were V β 13 ϩ (data not shown). This may indicate that not all primary CD4 ϩ T cells responding to EBV are directed against superantigen or it may reflect a difference in the protocols used. T cells were cultured for 21 days in our study compared to that of only 6 h culture in measuring the upregulation of CD69 used in detecting superantigen reactive T cells (28) . The immune system of seropositive individuals is regularly exposed to EBV lytic antigens in vivo as infectious virus is regularly shed in saliva and all infected individuals have antibody to virus capsid antigen (1, 3) . However, evidence defining which antigens are responsible for stimulating the CD4 ϩ T cells remains circumstantial and the role of EBV lytic cycle proteins in this process will only be resolved by considering each antigen in turn as has been done with the EBV latent antigens (15) . Nevertheless, the high numbers of CD4 T cells from both seronegative and seropositive donors which respond to EBV are likely to have an important role in the biology of the virus.
Our results show that CD4 ϩ T cells can prevent the growth both of LCL expressing EBV lytic cycle antigens and latently infected LCL. These observations suggest that, once activated, EBV-responsive CD4 ϩ T cells may be able to regulate LCL independently of specific antigen recognition. Apoptosis of activated lymphocytes through CD95-CD95L interaction is a central mechanism of immune regulation with respect to both T and B cells (29) (30) (31) . Apart from the expression of viral antigens, LCL have a phenotype almost identical to a conventional activated B cell (1) . Our data clearly demonstrate that the inhibition of LCL growth by EBVresponsive CD4 ϩ T cell lines involves the interaction of CD95L on the T cells with CD95 expressed on LCL. This mechanism of controlling virally infected cells may be of particular importance in infection with EBV since the virus targets B cells. In this respect, such inhibition may reflect a normal process of regulation within the immune system triggered simply as a result of the ability of EBV to induce an activated phenotype in B cells. No mechanistic link can yet be drawn between the increased number of CD4 ϩ T cells, apparently arising through viral lytic product stimulation, and CD95-CD95L-mediated apoptosis.
The importance of CD95-CD95L interactions in immune homeostasis has been emphasized by studies in mice. The lpr and gld strains of mice have mutations of CD95 and CD95L respectively, and both strains exhibit a high incidence of lymphoid tumours and lymphoproliferative autoimmune disease (32) . In this regard it is interesting to note the similar association of EBV with lymphoid tumours and the lymphoproliferative disease IM.
CD95L is predominately associated with T h 1-type cells (33) (34) (35) . A shift towards a T h 2 phenotype with loss of CD95-mediated killing and a concurrent increase in cytokines which support B cell growth could alter the balance of the immune response in favour of EBV. Differences between individuals in CD95-mediated killing and cytokine production by primary CD4 ϩ T cells responding to EBV may explain why infants rarely develop IM and only half of seronegative young adults develop IM (3) on primary infection. IM is characterized by high numbers of EBV-infected B cells in the circulation (36) which in turn stimulate overexpansion of oligoclonal CD8 ϩ T cells, some of which are specific for EBV latent and immediate early antigen peptides (37, 38) . CD4 ϩ T cells expressing CD95L could influence these events by (i) limiting growth of EBV-infected B cells and (ii) down-regulating the CD8 ϩ T cell response. The data reported here show that CD4 ϩ T cells can limit LCL growth in vitro. The continual decrease in the ratio of CD8 ϩ T cells to CD4 ϩ T cells in cultures repeatedly stimulated with PMA-activated LCL indicates EBV-reactive CD4 ϩ T cells may also limit the growth of CD8 ϩ T cells in vitro. We found no evidence that PMAactivated LCL themselves were directly responsible for downregulating CD8 ϩ T cells. CD95L was not detected on PMAactivated LCL nor were PMA-activated LCL able to directly inhibit growth of the CD95-susceptible T cell line Jurkat (data not shown).
Some further interesting observations were made from two seronegative individuals in this study. While the CD4 ϩ T cells from one were able to inhibit the growth of autologous LCL, those from the second individual were not and this second patient contracted IM 1 week after the completion of this study. We are currently seeking to collect data from a larger sample to ascertain if lack of CD95-mediated killing by primary CD4 ϩ T cells is indeed a characteristic feature of individuals susceptible to IM.
Corroborative evidence supporting a role for CD4 ϩ T cells in both the pathogenesis of IM and the subsequent control of EBV is provided by studies on murine gammaherpesvirus 68 (MHV68). This virus has many similarities to EBV, causes acute respiratory tract infection and latently infects B lymphocytes. MHV68 also induces a syndrome comparable to IM giving high numbers of activated CD8 ϩ T cells in peripheral blood. Evidence suggests that cytokines provided by CD4 ϩ T cells and a viral superantigen presented by MHC class II to V β 4 ϩ CD8 ϩ T cells are important in the pathogenesis of this syndrome (39) . Furthermore, under conditions of CD4 ϩ deficiency the initial lymphoproliferation does not occur and in the absence of CD4 ϩ T cells the CD8 ϩ T cells are unable to limit the progression of the virus infection (40) . The expression of CD95 on EBV-positive BL lines correlates with a shift towards a lymphoblastoid phenotype. However, unlike LCL the majority of BL lines expressing CD95 are not susceptible to CD95-mediated killing (41) . Recently it has been reported that EBV lymphomas from immunosupressed patients are susceptible to CD95-mediated killing (42) . Escape from immune surveillance is an important part of the pathogenesis of tumours. EBV B cell tumours in immunosupressed patients have a latent viral phenotype similar to LCL and are usually associated with infiltrating T cells (43) . It is possible that the T cells which infiltrate the tumour are not expressing CD95L and, therefore, are unable to eliminate the tumour. We have noticed that the CD4 ϩ T cell lines lose their ability to kill CD95-susceptible targets after prolonged culture in vitro and a similar situation could occur in vivo following chronic stimulation of CD4 ϩ T cells by lymphomas which express EBV antigens.
In contrast, endemic BL tumour cells express only EBNA1, have a reduced expression of TAP and MHC class I, and there is also a reduction in the expression of ICAM1, LFA3 and B7 (44, 45) . The resistance of BL cells to CD95-mediated killing adds another possible mechanism of immune avoidance (Fig. 3) (41) . Clearly more than one mechanism of avoidance of CD95 killing can occur in BL with some lines down-regulating CD95 expression and others (e.g. Raji) continuing to express CD95 but remaining refractory to CD95-mediated apoptosis through unknown mechanisms. Interactions between B and T cells involve multiple signals. For example, CD40-mediated signals up-regulate the expression of CD95 on EBV-negative BL lines and increase their susceptibility to CD4 ϩ killing (46) . Similar multiple signals may explain the observed partial inhibition of growth of Daudi cells by CD4 ϩ T cells.
The biology of EBV and its latency within the B cell compartment have led to the development of many adaptations that enable the virus to exploit the mechanisms of B cell growth and differentiation. Consequently, in addition to mechanisms of anti-viral immunity, normal mechanisms of immune regulation may be important in controlling the virus. To what extent the CD4 ϩ T cell CD95-CD95L-induced apoptosis of EBV-infected B cells described here specifically contributes to the anti-viral immunity is not yet clear. However, variations in immune regulation may contribute to the pathogenesis of disease caused by a virus that is usually harmless in the vast majority of individuals.
